Evidence map›Paper›PMID 33693149›Full record

ArticleCirculation reports2019

Safety and Efficacy of Ambrisentan-Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice.

Masaharu Kataoka, Toru Satoh, Hiromi Matsubara, Koji Yamamoto, Tsukasa Inada, Kazunari Umezawa, Tomohiko Takahashi, Atsushi Nakano, Keiichi Fukuda

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Circulation reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Masaharu KataokaDepartment of Cardiology, Keio University School of Medicine Tokyo Japan.
Toru SatohDepartment of Cardiology, Kyorin University School of Medicine Tokyo Japan.
Hiromi MatsubaraDepartment of Cardiology, National Hospital Organization Okayama Medical Center Okayama Japan.
Koji YamamotoDepartment of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences Aichi Japan.
Tsukasa InadaDepartment of Cardiology, Cardiovascular Center, Osaka Red Cross Hospital Osaka Japan.
Kazunari UmezawaMedical Affairs, GlaxoSmithKline K.K. Tokyo Japan.
Tomohiko TakahashiMedical Affairs, GlaxoSmithKline K.K. Tokyo Japan.
Atsushi NakanoMedical Affairs, GlaxoSmithKline K.K. Tokyo Japan.
Keiichi FukudaDepartment of Cardiology, Keio University School of Medicine Tokyo Japan.
GlaxoSmithKline (India) · INKeio University · JPKyorin University · JPNagoya City University · JPNational Hospital Organization · JPOsaka Red Cross Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AmbrisentanCombination therapyHemodynamicsPhosphodiesterase type 5 inhibitorPulmonary arterial hypertension

Identifiers

PMID33693149
PMCPMC7889478
OpenAlexW2947966032

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.